Free Trial
NASDAQ:BCYC

Bicycle Therapeutics (BCYC) Stock Price, News & Analysis

$22.66
+0.45 (+2.03%)
(As of 07/12/2024 08:51 PM ET)
Today's Range
$22.28
$24.05
50-Day Range
$19.58
$24.47
52-Week Range
$12.54
$27.50
Volume
249,400 shs
Average Volume
347,433 shs
Market Capitalization
$969.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$46.86

Bicycle Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
106.8% Upside
$46.86 Price Target
Short Interest
Bearish
6.57% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.42mentions of Bicycle Therapeutics in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$89,460 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($4.44) to ($5.01) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.22 out of 5 stars

Medical Sector

767th out of 912 stocks

Pharmaceutical Preparations Industry

359th out of 434 stocks

BCYC stock logo

About Bicycle Therapeutics Stock (NASDAQ:BCYC)

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

BCYC Stock Price History

BCYC Stock News Headlines

$5k to $1.3m in just 3 trades
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
$5k to $1.3m in just 3 trades
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
See More Headlines
Receive BCYC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bicycle Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/02/2024
Today
7/14/2024
Next Earnings (Estimated)
8/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:BCYC
Fax
N/A
Employees
284
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$46.86
High Stock Price Target
$65.00
Low Stock Price Target
$32.00
Potential Upside/Downside
+106.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

Net Income
$-180,660,000.00
Net Margins
-404.14%
Pretax Margin
-399.99%

Debt

Sales & Book Value

Annual Sales
$26.98 million
Book Value
$12.35 per share

Miscellaneous

Free Float
39,143,000
Market Cap
$969.39 million
Optionable
Optionable
Beta
0.93
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Dr. Kevin Lee M.B.A. (Age 56)
    Ph.D., CEO & Executive Director
    Comp: $1.35M
  • Sir Gregory Paul Winter CBE (Age 73)
    FMedsci, FRS, HonFRCP, HonFTSE, Co-Founder & Non-Executive Director
    Comp: $57.75k
  • Ms. Alethia Rene Young (Age 45)
    Chief Financial Officer
    Comp: $581.69k
  • Dr. Santiago Arroyo M.D. (Age 64)
    Ph.D., Chief Development Officer
    Comp: $916.98k
  • Dr. Christian Heinis
    Scientific Founder
  • Mr. Alistair Milnes (Age 50)
    Chief Operating Officer
    Comp: $796.09k
  • Mr. Travis Thompson
    Senior VP, Chief Accounting Officer & Principal Accounting Officer
  • Dr. Michael Skynner B.sc. Ph.d. (Age 55)
    Ph.D., Chief Technology Officer
    Comp: $881.01k
  • Dr. Nicholas Keen Ph.D. (Age 56)
    Chief Scientific Officer
  • Mr. Zafar Qadir
    General Counsel

BCYC Stock Analysis - Frequently Asked Questions

How have BCYC shares performed this year?

Bicycle Therapeutics' stock was trading at $18.08 at the beginning of the year. Since then, BCYC stock has increased by 25.3% and is now trading at $22.66.
View the best growth stocks for 2024 here
.

How were Bicycle Therapeutics' earnings last quarter?

Bicycle Therapeutics plc (NASDAQ:BCYC) announced its earnings results on Thursday, May, 2nd. The company reported ($0.62) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.25) by $0.63. The business's quarterly revenue was up 298.9% compared to the same quarter last year.

When did Bicycle Therapeutics IPO?

Bicycle Therapeutics (BCYC) raised $64 million in an IPO on Thursday, May 23rd 2019. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity was co-manager.

Who are Bicycle Therapeutics' major shareholders?

Top institutional investors of Bicycle Therapeutics include Harbor Capital Advisors Inc. (0.13%). Insiders that own company stock include Kevin Lee, Michael Skynner, Nicholas Keen, Nigel Crockett, Alistair Milnes, Lee Kalowski, Travis Alvin Thompson, Michael Charles Ferguso Hannay, Stephen B Alexander and Pierre Legault.
View institutional ownership trends
.

How do I buy shares of Bicycle Therapeutics?

Shares of BCYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Bicycle Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Bicycle Therapeutics investors own include Aldeyra Therapeutics (ALDX), AVEO Pharmaceuticals (AVEO), Fulcrum Therapeutics (FULC), Mersana Therapeutics (MRSN), AbbVie (ABBV), Adverum Biotechnologies (ADVM) and Agenus (AGEN).

This page (NASDAQ:BCYC) was last updated on 7/15/2024 by MarketBeat.com Staff

From Our Partners